3D PATHOLOGY / Illumos

A NEW DIMENSION IN CANCER ASSESSMENT

5-Minute Cancer Diagnosis
by 3D Pathology

Biopsy to image in five minutes. The whole specimen. At the point of care.

Discuss a clinical collaboration

WHY 3D PATHOLOGY?

Because cancers can hide in a single plane.
But most doctors are looking at ONE plane now.

Less than

1%

Tissue examined

Of tissue volume in conventional pathology, as a limitation of physical sectioning of tissue.

Up to

25%

Cancer missed in the same tissue

Of lung cancer patients with an initially negative lung biopsy had cancer missed in that same biopsy tissue.

Up to

30%

Repeat lung biopsy needed

Due to non-diagnostic results, such as insufficient quantity, atypical cells and so on.

Sampling impacts accuracy. Accuracy determines outcomes.

THE WORKFLOW

Three steps. A new perspective.

01

Illustration of biopsy tissue immersed in clear fluid in a closed clinical specimen bottle with a white screw cap.

Fresh intact biopsy tissue is fixed, stained and cleared in patented solutions

02

The entire tissue is imaged using a portable laser microscope

03

Pathologists remotely review the image stack in real time and provide feedback

TISSUE TO IMAGE

≈5 minutes

What makes 3D pathology different?

FFPE (conventional pathology)

Frozen section

3D pathology “Speedrun”

Tissue volume examined

<1%

<1%

100%

Sectioning method

Physical (microtome)

Physical (cryostat)

Optical (laser scanning microscopy)

Tissue condition after testing

Partially consumed by sectioning

Partially consumed; freezing artifacts may persist

Fully intact

Same examined tissue usable for downstream tests (e.g. IHC, NGS)

No, tissue is depleted with each section

No, tissue is depleted with each section

Yes; the same tissue is compatible with validated downstream analyses

Image quality

Good (gold standard)

Lower; with ice-crystal artifacts

Comparable to FFPE

Turnaround time

Days to weeks

~20–45 minutes

~5 minutes

Location

Pathology lab

Pathology lab

Point of care, with remote pathologist access

CLINICAL STUDIES IN PROGRESS

Across tissue types. Toward clinical evidence.

Multiple clinical studies are in progress across different tissue types and clinical applications.

Generated grayscale anatomical illustration of the lungs; illustrative, not a clinical image.

Lung biopsy

Generated grayscale anatomical illustration of the colon; illustrative, not a clinical image.

Colonic polyp

Generated grayscale anatomical illustration of the prostate; illustrative, not a clinical image.

Prostate biopsy

Generated grayscale anatomical illustration of the bladder; illustrative, not a clinical image.

Bladder cancer

Generated grayscale anatomical illustration of the brain; illustrative, not a clinical image.

Brain tumor

Generated grayscale cartoon illustration of skin layers and a hair follicle; illustrative, not a clinical image.

Skin cancer

A better future

How 3D pathology is changing the patient journey.

01

ASSESSMENT

Improved diagnostic accuracy

02

DIAGNOSIS

Early diagnosis and intervention

03

DURING SURGERY

Timely feedback on sample adequacy and margin status

04

OPERATIVE CARE

Reduced operating time

05

FOLLOW-UP

Reduced repeat biopsy and reoperation rates

06

LONG-TERM IMPACT

AI pathology and biomarker discovery

Rich 3D tissue data could support AI model development and the discovery of new spatial biomarkers.

Bring your clinical question.

Tell us how 3D pathology can help your patients. Together we can make it come true.

3D PATHOLOGY / ILLUMOS · For professional collaboration inquiries. · Hong Kong, US